Irritable bowel syndrome is a type of functional bowel disorder causing symptoms of abdominal pain and altered bowel habits such as diarrhoea (IBS-D) and constipation (IBS-C). This book uses the 'whole evidence' approach to give an overview of the available evidence for Chinese medicine treatment for irritable bowel syndrome, particularly subtypes IBS-D and IBS-C.The book starts by summarising the conventional understanding of irritable bowel syndrome, including its subtypes, aetiology, diagnosis and current available treatments. Data from Chinese medicine classical literature and clinical studies are then discussed. Evidence from clinical studies are evaluated using high-quality and rigorous scientific methodology. For IBS-D and IBS-C, evidence from treatment modalities including Chinese herbal medicine, acupuncture and combination Chinese medicine therapies are presented. The findings are analysed and potential implications for clinical practice and research are explored. Experimental studies that describe the potential mechanisms of action of key herbs are summarised. In the final chapter, current evidence of Chinese medicine for IBS-D and IBS-C are synthesised, recommendations for contemporary clinical practice and future research are also offered.The book is a helpful guide for clinicians and students of Chinese and integrative medicine, offering a comprehensive synthesis of both classical and contemporary knowledge that can integrated into their clinical practice for people with irritable bowel syndrome.

This comprehensive update on irritable bowel syndrome addresses both the state of art diagnosis and treatment as well as emerging therapies and future directions. Worldwide authority, Dr. Eammon Quigley, contributes an article on Therapies Aimed at the Gut Microflora and Inflammation. Other highlights include articles devoted to genetics, biomarkers, and symptom-based diagnostic criteria.

This two-part issue of Endocrinology and Metabolism Clinics of North America provides the endocrinologist with comprehensive essential updates about tumors of the gastroenteropancreatic system. Topics covered include the history and development of the gastroenteropancreatic endocrine axis; the changing face and epidemiology of neuroendocrine tumors (NETs); chromogranins current state of the art, pathology of gastroenteropancreatic (GEP) disorders; new and emerging syndromes related to gastrointestinal (GI) hormones; an update on incretins; prospects for ghrelin in the clinic, obesity/appetite and hedonism; GI motility disorders; gastric bypass and GI hormones; pancreatic exocrine function and GI hormones; harnessing the pancreatic stem cell; how to diagnose NETs before there are METs; NETs in kids: combining the SEER data for children and adults with site differences; novel biomarkers for NETs; standard imaging techniques for NETs; novel peptide imaging: glucagon receptor; signaling mechanism in NETs as targets for therapy; update on clinical trials; nutrition and the GEP; peptide radiotherapy; in vitro analysis of NETs: the role of angiogenesis; modern lab evaluation of peptide and amines: a continuing role for radioimmunoassay?; surgery/surgical management of NETs; and evaluation and quality of life in NETs patients.

Dr. Hunt has assembled a group of top experts to discuss the newest and most successful medical therapies to treat gastrointestinal diseases.? The issue is divided into sections devoted to each of these diseases states or disorders: ? acid-related disorders, functional gastrointestinal disorders, inflammatory bowel disease, gastrointestinal oncology, and hepatitis; the last 2 articles address the future directions in gastrointestinal pharmacotherapy.? Articles of special interest include those on? Anti-TNFa Drugs and New Biological Drugs for IBD, 5-ASA Drugs and Modified Formulations, and Potential for Manipulation of the Microbiome in Gastrointestional Disease

Dr. Allen's issue focuses on how gastroenterologists can maximize the "value? of colonoscopy - where value is defined as quality/cost. Clinical issues are covered, like sedation issues, complications of colonoscopy, and infection risk, but the majority of the articles deal with the discussions that surround quality colonoscopy-articles like: Risk Management and Legal Issues for Colonoscopy; Cost effectiveness of Colonoscopy in Prevention of Colon Cancer; Efficacy and Effectiveness of Colonoscopy: How Do We Bridge the Gap?; Current State of Colonoscopy Performance Measures; Use of Databases and Registries to Enhance Quality; and Maximizing the Value of Colonoscopy in Community, to name a few. In preparation of the changing landscape of healthcare, this issue will be an important one for all practicing gastroenterologists.

Dr. Soetikno has organized a comprehensive issue devoted to the detection and diagnosis of non-polypoid colorectal neoplasms with special emphasis on sessile or flat colon adenoma.? Top experts in the field have supplied the latest clinical information in the following areas: Non-Polypoid Colorectal Neoplasms in Ulcerative Colitis; Detection and Diagnosis of Non-Polypoid Colorectal Neoplasms; Image-Enhanced Endoscopy to Detect and Diagnose Non-Polypoid Colorectal Neoplasms; CT Colonography and Non-Polypoid Colorectal Neoplasms, as well as Endoscopic Mucosal Resection of Non-Polypoid Colorectal Neoplasms.? This issue is an important one as there are not many references on the topics that are as comprehensive.

This two-part issue of Endocrinology and Metabolism Clinics of North America provides the endocrinologist with comprehensive essential updates about tumors of the gastroenteropancreatic system.? Topics covered include the history and development of the gastroenteropancreatic endocrine axis; the changing face and epidemiology of neuroendocrine tumors (NETs); chromogranins current state of the art, pathology of gastroenteropancreatic (GEP) disorders; new and emerging syndromes related to gastrointestinal (GI) hormones; an update on incretins; prospects for ghrelin in the clinic, obesity/appetite and hedonism; GI motility disorders; gastric bypass and GI hormones; pancreatic exocrine function and GI hormones; harnessing the pancreatic stem cell; how to diagnose NETs before there are METs; NETs in kids: combining the SEER data for children and adults with site differences; novel biomarkers for NETs; standard imaging techniques for NETs; novel peptide imaging: glucagon receptor; signaling mechanism in NETs as targets for therapy; update on clinical trials; nutrition and the GEP; peptide radiotherapy; in vitro analysis of NETs: the role of angiogenesis; modern lab evaluation of peptide and amines: a continuing role for radioimmunoassay?; surgery/surgical management of NETs; and evaluation and quality of life in NETs patients.

'The Year Book of Gastroenterology' brings you abstracts of the articles that reported the year's breakthrough developments in gastroenterology, carefully selected from more than 500 journals worldwide. Expert commentaries evaluate the clinical importance of each article and discuss its application to your practice.

Dr. Kiesslich secured authors who are at the top of their field in GI Imaging to write articles that will serve as an up-to-date source for all gastroenterologists.? The issue is divided into sections devoted to imaging of the esophagus, stomach, small bowel, liver& pancreas, and colon; two articles are devoted to molecular imaging.? Readers will be very interested in the articles devoted to Contrast Enhanced and 3D-Endosonography, High Definition and Filter Aided Colonoscopy, and Autofluorescence and NBI Imaging in Barrett's Esophagus.

This book describes the latest research on the gut-kidney axis of ureic solutes; the toxico-pathological mechanisms of uremic toxin-induced organ failure, including kidney and cardiovascular tissue; and the preventive therapeutic strategies for uremia and related organ failure associated with kidney injuries and diseases. Retained uremic toxins cause a variety of symptoms, such as hypertension, fatigue, renal anemia, osteoporosis and neurologic impairment, which are apparent in chronic kidney disease (CKD) patients. The human gastrointestinal tract contains trillions of microorganisms, referred to as gut microbiota, which support the host metabolism by producing nutrients, such as vitamins and short-chain fatty acids. However, they also produce various harmful uremic toxins that show renal and cardiovascular toxicity, and correlate with an increased mortality in CKD patients. The composition and balance of gut microbiota are associated with the accumulation of uremic toxins and the pathophysiology of CKD, and as such are being considered for a novel therapeutic strategy.

Recent Advances in Gastroenterology: 13 is the ideal resource for keeping abreast of new developments within this fast moving field. Written by expert authors and featuring topics such as genetic-epidemiology of oesophageal cancer, polyposis syndromes and liver disease in pregnancy, each chapter introduces important principles that can be implemented into day to day treatment of GI disorders. Recent Advances in Gastroenterology: 13 is an invaluable revision tool for trainees, and a useful companion to practising gastroenterologists wishing to stay current in all aspects of this field. 11 chapters summarising important recent advances within the field of gastroenterology All topics are written in a practical and clinically relevant manner, further enhanced by the 'key clinical points for practice' sections at the end of each chapter Provides an effective exam revision tool for gastroenterology portion of the MRCP(UK) and the SCE in Gastroenterology All chapters written by expert authors ensuring authoritative and accurate content Full colour photographs throughout

This issue focuses on the latest cutting-edge research in GI diseases that have or may have an infectious origin, including gallbladder disease, gastric cancer, inflammatory bowel disease and others.

As the debate continues about who should perform CT Colonography, radiologists or endoscopists, this issue marks the first time that the debate is addressed in great detail by BOTH endoscopists AND radiologists. As a result, this issue will be of great interest to both groups. Both offer their point of view on this screening method in great detail. Articles include: Only Radiologists Should Read CT Colonography; Gastroenterologists Should Read CT Colonography; Small and Medium Sized Polyps Noted at CT Colonography Need Not Be Reported; Small and Medium Sized Polyps Noted at CT Colonography Should Be Reported; Role of CTC in a Colorectal Cancer Screening Program; and Establishing a CT Colonography Service, to name a few.

This volume addresses common issues and diseases of the gallbladder.? The majority of articles discuss gallstones, including their epidemiology, pathogenesis, and endoscopic, surgical, and medical therapy.? Additional chapters address current modalities to image the gallbladder, including endoscopic ultrasound.? The remaining chapters address management of other gallbladder diseases including gallbladder cancer, acalculous cholecystitis, polyps, and dysmotility.

This book provides a concise, state-of-the-art overview of occult GI bleeding. The text reviews the epidemiology, screening and detection methods for localization, and prominent treatment strategies for occult GI bleeding. It also features a dedicated section on special patient populations including children, premenopausal women, older adults, and patients with other predisposing, and complicating medical conditions. This volume is supplemented with numerous color illustrations, photographs, and table, and is one of the few dedicated resources on occult GI bleeding. Written by experts in the field, Management of Occult GI Bleeding: A Clinical Guide is a valuable resource for clinicians, practitioners, and students who are involved in the treatment of patients with occult GI bleeding.

Given the prevalence of obesity, any physician providing clinical care will be involved in the care of obese patients. Gastroenterologists will play an active role in the evaluation and treatment of these patients. Thereby, it is essential to fully understand the scope of the problem and the opportunities for intervention. The expert authors assembled for this issue offer expanded insight which can enhance care plans provided to this patient population. Since Dr. Johnson's first issue published, there are several updates in this area, and the articles in this volume address those.? These updates are seen in the areas of medical therapy, surgical options, and endoscopic treatments for obese patients.

The Guest Editors for this issue have assembled top experts to discuss only those most challenging aspects of diagnosis and treatment of inflammatory bowel disease. Emphasis is on comparing treatment paradigms, current and future biologics agents, safety profile of therapeutics, and novel diagnostic and prognostic tools for IBD. Articles are also devoted to pregnancy and IBD, IBD in children, and post-operative management of IBD.

The use of interventional endoscopy of the biliary and pancreatic ducts has increased dramatically in recent years. Although choledocholithiasis is the most common reason for endoscopic treatment, other indications include pancreatolithiasis, cholangitis, biliary pancreatitis, papillary stenosis, sphincter of Oddi dysfunction, and benign or malignant ductal strictures. The Guest Editor has assembled an issue full of expert authors to present state-of-the art information biliary and pancreatic endoscopy procedures and techniques.

Dr. Wolfsen presents information in this issue about endoluminal techniques that have been developed for removing Barrett's esophagus. Emphasis is on circumferential balloon-based radiofrequency ablation, ALA and porfimer sodium photodynamic therapy (PDT), endoscopic mucosal resection, submucosal dissection, and liquid nitrogen and carbon dioxide cryotherapy. Dr. Wolfsen's assembled authors also provide insight into advances in esophageal surgery, NOTES, and advances in the use of stents. The reader will find that the whole issue addresses the goal of moving closer to ideal endoscopic treatment modalities for the safe, effective, reproducible, stable, and durable treatment for Barrett's disease in order to prevent the development of dysplasia or carcinoma.

Aging is associated with an increased prevalence of several GI disorders, including those induced by drugs (eg, gastrointestinal bleeding caused by nonsteroidal anti-inflammatory drugs), anorexia of aging, development of constipation, diarrhea or fecal incontinence, and postprandial hypotension. This issue addresses these disorders and discusses the current treatments for management of these patients. Specifically, articles focus on celiac disease, anorexia of aging, chronic constipation, fecal incontinence, neurogastrointestinal diseases, ischemic gut, and the pharmacology of commonly used GI drugs.